Juan P Gonzalez-Rivas1, Jeffrey I Mechanick2, Maria M Infante-Garcia3, Jose R Medina-Inojosa4, Iuliia Pavlovska5, Ota Hlinomaz6, Petr Zak7, Sarka Kunzova6, Ramfis Nieto-Martinez8, Mária Skladaná6, Jan Brož9, Jose Pantaleon Hernandez6, Francisco Lopez-Jimenez4, Gorazd B Stokin6. 1. Department of International Clinical Research Center (ICRC), St Anne's University Hospital (FNUSA), Brno, Czech Republic; Harvard University T H Chan School of Public Health, Department of Global Health and Population Boston, Massachusetts. Electronic address: juan.gonzalez@fnusa.cz. 2. Icahn School of Medicine at Mount Sinai, The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Heart, and Division of Endocrinology, Diabetes and Bone, New York, New York. 3. Foundation for Clinic, Public Health, and Epidemiological Research of Venezuela (FISPEVEN), Caracas, Venezuela. 4. Mayo Clinic Preventive Cardiology, Rochester, Minnesota. 5. Department of International Clinical Research Center (ICRC), St Anne's University Hospital (FNUSA), Brno, Czech Republic; Department of Public Health, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 6. Department of International Clinical Research Center (ICRC), St Anne's University Hospital (FNUSA), Brno, Czech Republic. 7. Diabetology Department, St Anne's University Hospital (FNUSA), Brno, Czech Republic. 8. Harvard University T H Chan School of Public Health, Department of Global Health and Population Boston, Massachusetts; LifeDoc Diabetes and Obesity Clinic, Memphis, Tennessee. 9. Charles University Second Faculty of Medicine, Department of Internal Medicine, Praha, Czech Republic.
Abstract
OBJECTIVE: To determine the prevalence rate and associated risk factors for each stage of the Dysglycemia-Based Chronic Disease (DBCD) model, which 4 distinct stages and prompts early prevention to avert Diabetes and cardiometabolic complications. METHODS: Subjects between 25 and 64 years old from a random population-based sample were evaluated in Czechia from 2013 to 2014 using a cross-sectional design. DBCD stages were: stage 1 "insulin resistance" (inferred risk from abdominal obesity or a family history of diabetes); stage 2 "prediabetes"(fasting glucose between 5.6 and 6.9 mmol/L); stage 3 "type 2 diabetes (T2D)" (self-report of T2D or fasting glucose ≥7 mmol/L); and stage 4 "vascular complications" (T2D with cardiovascular disease). RESULTS: A total of 2147 subjects were included (57.8% women) with a median age of 48 years. The prevalence of each DBCD stage were as follows: 54.2% (stage 1); 10.3% (stage 2), 3.7% (stage 3); and 1.2% (stage 4). Stages 2 to 4 were more frequent in men and stage 1 in women (P < .001). Using binary logistic regression analysis adjusting by age/sex, all DBCD stages were strongly associated with abnormal adiposity, hypertension, dyslipidemia, and smoking status. Subjects with lower educational levels and lower income were more likely to present DBCD. CONCLUSION: Using the new DBCD framework and available metrics, 69.4% of the population had DBCD, identifying far more people at risk than a simple prevalence rate for T2D (9.2% in Czechia, 2013-2014). All stages were associated with traditional cardiometabolic risk factors, implicating common pathophysiologic mechanisms and a potential for early preventive care. The social determinants of health were related with all DBCD stages in alarming proportions and will need to be further studied.
OBJECTIVE: To determine the prevalence rate and associated risk factors for each stage of the Dysglycemia-Based Chronic Disease (DBCD) model, which 4 distinct stages and prompts early prevention to avert Diabetes and cardiometabolic complications. METHODS: Subjects between 25 and 64 years old from a random population-based sample were evaluated in Czechia from 2013 to 2014 using a cross-sectional design. DBCD stages were: stage 1 "insulin resistance" (inferred risk from abdominal obesity or a family history of diabetes); stage 2 "prediabetes"(fasting glucose between 5.6 and 6.9 mmol/L); stage 3 "type 2 diabetes (T2D)" (self-report of T2D or fasting glucose ≥7 mmol/L); and stage 4 "vascular complications" (T2D with cardiovascular disease). RESULTS: A total of 2147 subjects were included (57.8% women) with a median age of 48 years. The prevalence of each DBCD stage were as follows: 54.2% (stage 1); 10.3% (stage 2), 3.7% (stage 3); and 1.2% (stage 4). Stages 2 to 4 were more frequent in men and stage 1 in women (P < .001). Using binary logistic regression analysis adjusting by age/sex, all DBCD stages were strongly associated with abnormal adiposity, hypertension, dyslipidemia, and smoking status. Subjects with lower educational levels and lower income were more likely to present DBCD. CONCLUSION: Using the new DBCD framework and available metrics, 69.4% of the population had DBCD, identifying far more people at risk than a simple prevalence rate for T2D (9.2% in Czechia, 2013-2014). All stages were associated with traditional cardiometabolic risk factors, implicating common pathophysiologic mechanisms and a potential for early preventive care. The social determinants of health were related with all DBCD stages in alarming proportions and will need to be further studied.
Authors: Jan S Novotný; Juan P Gonzalez-Rivas; Jose R Medina-Inojosa; Francisco Lopez-Jimenez; Yonas E Geda; Gorazd B Stokin Journal: Alzheimers Dement (N Y) Date: 2021-12-31
Authors: Iuliia Pavlovska; Anna Polcrova; Jeffrey I Mechanick; Jan Brož; Maria M Infante-Garcia; Ramfis Nieto-Martínez; Geraldo A Maranhao Neto; Sarka Kunzova; Maria Skladana; Jan S Novotny; Hynek Pikhart; Jana Urbanová; Gorazd B Stokin; Jose R Medina-Inojosa; Robert Vysoky; Juan P González-Rivas Journal: Nutrients Date: 2021-07-08 Impact factor: 6.706